Literature DB >> 19781699

Immune response deviation and enhanced expression of chemokine receptor CCR4 in TBI patients due to unknown serum factors.

Dieter Cadosch1, Mohamed S Al-Mushaiqri, Oliver P Gautschi, Erwin Chan, Florian J Jung, Allan P Skirving, Luis Filgueira.   

Abstract

BACKGROUND: Severe brain trauma leads to an activation of the immune system. To this date, neither the exact perturbation of the specific immune reaction induced by the traumatic brain injury (TBI), nor the interactions leading to the infiltration of peripheral immune cells into the brain are fully understood. PATIENTS AND METHODS: Serum was collected from 17 patients with TBI and a long bone fracture, 24 patients with an isolated long bone fracture and from healthy individuals. The effect of the serum on normal human monocytes and T-lymphocytes was tested in vitro by assessing proliferation and expression of surface markers, chemokine receptors and cytokines.
RESULTS: Serum collected from patients with a TBI and a long bone fracture increased the expression of the chemokine receptor CCR4 in monocytes when compared to patients with an isolated long bone fracture. Extending this comparison to T-lymphocytes, the serum from TBI patients induced lower proliferation rates and decreased expression of the pro-inflammatory cytokine TNF-alpha, while simultaneously increasing the secretion of immune-modulatory cytokines (IL-4, IL-10 and TGF-beta) (p<0.05).
CONCLUSION: Patients with a TBI release currently unknown soluble factors into the circulating blood that up regulate expression of chemokine receptor CCR4 in peripheral blood monocytes whilst concurrently inducing expression of immunosuppressive cytokines by activated T-lymphocytes. Copyright 2009 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19781699     DOI: 10.1016/j.injury.2009.09.001

Source DB:  PubMed          Journal:  Injury        ISSN: 0020-1383            Impact factor:   2.586


  3 in total

1.  Recombinant human interleukin-1 receptor antagonist in severe traumatic brain injury: a phase II randomized control trial.

Authors:  Adel Helmy; Mathew R Guilfoyle; Keri L H Carpenter; John D Pickard; David K Menon; Peter J Hutchinson
Journal:  J Cereb Blood Flow Metab       Date:  2014-02-26       Impact factor: 6.200

Review 2.  Clinical evidence of inflammation driving secondary brain injury: a systematic review.

Authors:  Holly E Hinson; Susan Rowell; Martin Schreiber
Journal:  J Trauma Acute Care Surg       Date:  2015-01       Impact factor: 3.313

3.  Recombinant CCL17-dependent CCR4 activation alleviates neuroinflammation and neuronal apoptosis through the PI3K/AKT/Foxo1 signaling pathway after ICH in mice.

Authors:  Shuixiang Deng; Peng Jin; Prativa Sherchan; Shengpeng Liu; Yuhui Cui; Lei Huang; John H Zhang; Ye Gong; Jiping Tang
Journal:  J Neuroinflammation       Date:  2021-03-01       Impact factor: 8.322

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.